PSMA PET is used for initial staging of patients with high-risk prostate cancer, localization of biochemical recurrence, and for evaluation of tumor PSMA expression prior to radioligand therapy (Fendler et al. 2023). The gene discussed is FOLH1; the disease is prostate cancer.